Please Authorize In and usage this article’s on page print button to print this article.
West Cancer Focus opens revolutionary brand-new facility
West Cancer Focus opens ‘relentlessly progressive’ location
The West Cancer Focus is rolling out a brand-new non-invasive treatment for Glioblastoma Multiforme (GBM), a kind of mind cancer.
Optune, a machine that uses low-intensity electric fields to kill cancer cells, is now offered for patients at the West Cancer Center.
“The Optune technology is reflective of West Cancer Center’s multidisciplinary method to comprehensive cancer care and is indicative of our commitment to create a world-class Comprehensive Neuro-Oncology Program,” said Ballo. “We actually believe in the easy science behind this and are seeking brand-new possibilities along with the firm for expanding its usage through Phase I through III clinical trials and neurocognitive studies.”
Upcoming Events
]]>
In addition to the Optune treatment, a brand-new collaboration along with Semmes Murphey Clinic will certainly lead to the launch of West Cancer Center’s Comprehensive Neuro-Oncology Program. The comprehensive Regimen will certainly be led by West Cancer Focus medical oncologist Manjari Pandey; Matthew Ballo, West Cancer Center’s director of radiation oncology; and Semmes Murphey neurosurgeons Jeff Sorenson and Madison Michael.
“Our vision for the Neuro-Oncology Regimen is to supply the current and greatest in medical therapeutics while focusing on the total well-being of our patients and their families. We are happy to have the ability to supply Optune™ to our patients; it actually is the brand-new standard of care for Glioblastomas,” said Pandey. “Our collaborative efforts are geared to determining newer indications for this technology and to identify a lot more patients that would certainly benefit.”
A primary focus for the Comprehensive Neuro-Oncology Regimen will certainly be investigative research and improvement of care for GBM through Optune therapy. The device’s FDA approval was based on outcomes of a randomized Phase III study that indicated total survival paces for newly diagnosed GBM patients treated along with Optune were as a lot as 50 percent greater compared to those treated along with standard chemotherapy alone. The Optune cap is intended to be used a minimum of 18 hrs per day and has actually revealed improved cognitive function and quality of life. The treatment was previously approved for usage in 2011 as a monotherapy for recurrent GBMs.
“The treatment preparation collaboration in between Semmes Murphey and West Cancer Focus is a real demonstration of the triumph of multidisciplinary care within our Mid-South community,” said Erich Mounce, CEO of West Cancer Center. “This is one more example of the groundbreaking job our West Cancer Focus physicians and researchers are carrying out every solitary day, ideal listed here in Memphis.”
Michael Sheffield covers bioscience and biotechnology; manufacturing; tourism and hospitality; and sports business. Contact him or her at msheffield@bizjournals.com.
0 comments
Post a Comment